Navigation Links
Absorption Systems Partners with Synerzys to Promote Biopharmaceutics Classification System (BCS) Testing of Drugs

EXTON, Pa., April 8, 2013 /PRNewswire/ -- The preclinical contract research organization Absorption Systems, a global leader in pharmacokinetic testing of drugs, announces that it has entered into a partnership with the Indian pharmaceutical consulting firm Synerzys Lifecare Pvt Ltd. The intent of the partnership is two-fold: to sell Absorption Systems' services in India and, more broadly, to expand the use of the Biopharmaceutics Classification System (BCS) throughout the world.

The BCS, first implemented by the US Food and Drug Administration (USFDA) in 2000, is a scientifically sound regulatory pathway that classifies drugs in such a way as to eliminate the need for human testing or provide further scientific evidence supporting human testing. As a result, drug sponsors can save significant time and money in the development of their products, especially for generics. For developing nations in general, it also means that more-affordable generic drugs can be made available sooner to patients who need them but cannot afford most new drugs. Regulatory authorities around the world are embracing the BCS in various capacities, and as the dissemination of more scientific evidence emerges the drive to further embrace the BCS is clear.

Absorption Systems is the world leader in the measurement of drug permeability for BCS classification. As a result, the company has been audited several times by the USFDA and is registered with the agency as a GDUFA (Generic Drug User Fee Amendments) testing facility. In spite of the trend of American drug companies outsourcing drug research, manufacturing, and clinical trials to China and India, Absorption Systems has established a growing business in the opposite direction. Expertise has no boundaries.

Synerzys is a pharmaceutical consulting and advisory firm based in Mumbai, India. Its team has broad experience in all aspects of drug development and strong connections with all major Indian drug companies. Synerzys is ideally situated due to the fact that  India is the world's fourth-largest producer of pharmaceuticals by volume, accounting for roughly 8% of global production. Of the 2,244 abbreviated new drug applications (generics) approved by the USFDA in the 5-year period from 2007-2011, 31% (694) were for Indian sponsors.

Patrick Dentinger, President and CEO of Absorption Systems, commented that, "The growing acceptance of the BCS has created the need for a more strategic view of India. In the low-margin, first-to-file world of generic drug products, companies will either use the BCS approach or compete with it."

Kaushal Shah, COO of Synerzys, added, "We are very happy to partner with Absorption Systems in an endeavour that has the potential for mutual commercial success as well as real benefits to patients in many countries."

About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, in San Diego, CA, and in Panama City, Panama, and serves customers throughout the world. For information on the company's comprehensive contract services and applied research programs, please visit  

About Synerzys Lifecare Pvt Ltd.
Synerzys Lifecare is a global pharma advisory firm specializing in consulting and execution for Strategy Planning, Business Development, & Licensing. Synerzys provides end-to-end healthcare business solutions enabling you to surpass your short-term as well as long-term goals.

We believe that Rest of the World (RoW) and Emerging Markets (EM) will drive the growth of healthcare in the coming decades. However, with increasing opportunity comes increasing competition. In this challenging and changing business landscape, you constantly need a partner who can not only provide innovative solutions but also help in meticulous execution. Know us more, examine what drives us at

Chris Bode , Ph.D.
VP Scientific & Corporate Communications
Absorption Systems

Kaushal Shah , B. Pharm, MBA
COO, Synerzys
+91 93221 44736

SOURCE Absorption Systems
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Absorption Systems Registers with FDA as a Generic Drug Facility under GDUFA
2. Absorption Systems announces novel test platform for interactions with the BCRP transporter
3. Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the First Quarter Ended March 31, 2013
4. Varian Medical Systems Appoints Deepak "Dee" Khuntia M.D. Vice President of Medical Affairs
5. MAQUET Medical Systems USA Launches The MIRA-i CS Retractor System For Use During Minimally Invasive Revascularization Procedures
6. Johnson Electric Launches Medication Dosing Systems
7. Two of Psyche Systems Customers to Speak at 2013 Executive War College
8. Varian Medical Systems Schedules Mid-Year Review with Investors in New York
9. Patch Pump Drug Delivery Systems - Devices, Markets, Players and Prospects
10. South Jersey Healthcare Selects Perioperative Management By Surgical Information Systems
11. Positive Data, Pipeline Improvements & Market Expansion - Research Report on Abbott Laboratories, Stryker Corporation, St. Jude Medical, Cardiovascular Systems and MAKO Surgical
Post Your Comments:
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)... 2015 ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... ... Effective immediately, every single IguanaMed scrub style will be available at Target via ... “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” for a limited ... price. , IguanaMed’s mission is to outfit every healer around the world ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Safe storage for ... of two inventors, one from Lakewood, New Jersey and the other from Bradley Beach, ... patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often than ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again ... choose from, the possibilities are endless. Users have full control over angle of view, ... masking effects, users are sure to get heads to turn. , ProPanel: Pulse offers ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 6th ... the University of British Columbia suggested that laws requiring bicyclists to wear helmets may ... part of the reason for the controversial conclusion is that, while helmets have certainly ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
Breaking Medicine News(10 mins):